



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 21-372

Helsinn Healthcare S.A.  
c/o August Consulting  
Attention: Craig Lehmann, Pharm. D.  
515 Capital of Texas Highway, Suite 150  
Austin, TX 78746

Dear Dr Lehmann:

Please refer to your new drug application (NDA) dated September 26, 2002, received September 27, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Aloxi™ (palonosetron hydrochloride injection).

We acknowledge receipt of your submissions dated October 11 and November 21, 2002 and January 24, April 9, April 24, May 15, June 6, June 9, June 13, June 16, June 18, June 20, June 25, July 1, July 17, and July 22, 2003.

This new drug application provides for the use of Aloxi™ (palonosetron hydrochloride injection) for:

- 1) the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, and
- 2) the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Please note that, based on the primary stability data submitted, we are granting a 24-month expiration period for this product. When additional stability data are available, an extension of the expiration period may be requested by submission of a prior approval supplemental new drug application.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and submitted labeling (carton label submitted June 25, 2003 and immediate container label submitted July 1, 2003). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved NDA 21-372." Approval of this submission by FDA is not required before the labeling is used.

HIGHLY CONFIDENTIAL - OUTSIDE COUNSEL EYES ONLY

HELNS0387519

NDA 21-372

Page 2

FDA's Pediatric Rule [at 21 CFR 314.55/21 CFR 601.27] was challenged in court. On October 17, 2002, the court ruled that FDA did not have the authority to issue the Pediatric Rule and has barred FDA from enforcing it. Although the government decided not to pursue an appeal in the courts, it will work with Congress in an effort to enact legislation requiring pharmaceutical manufacturers to conduct appropriate pediatric clinical trials. In addition, third party interveners have decided to appeal the court's decision striking down the rule. Therefore, we encourage you to submit a pediatric plan that describes development of your product in the pediatric population where it may be used. Please be aware that whether or not this pediatric plan and subsequent submission of pediatric data will be required depends upon passage of legislation or the success of the third party appeal. In any event, we hope you will decide to submit a pediatric plan and conduct the appropriate pediatric studies to provide important information on the safe and effective use of this drug in the relevant pediatric populations.

The pediatric exclusivity provisions of FDAMA as reauthorized by the Best Pharmaceuticals for Children Act are not affected by the court's ruling. Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products. You should refer to the Guidance for Industry on Qualifying for Pediatric Exclusivity (available on our web site at [www.fda.gov/cder/pediatric](http://www.fda.gov/cder/pediatric)) for details. We acknowledge your June 26, 2003 "Proposed Pediatric Study Request" submitted under IND 39,797. We are reviewing your submission and will respond to your proposal in a separate letter. FDA generally does not consider studies submitted to an NDA before issuance of a Written Request as responsive to the Written Request. Applicants should obtain a Written Request before submitting pediatric studies to an NDA.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). In addition, we request that you initiate a 15-day report [21 CFR 314.80(c)] for each of the following:

- All spontaneous reports of constipation requiring hospitalization or emergency room visit
- All spontaneous reports of possible complications of constipation such as obstruction, perforation, intestinal ulceration, toxic megacolon, ileus, or impaction resulting in hospitalization or emergency room visit
- All spontaneous reports of any cardiovascular adverse event

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics

NDA 21-372

Page 3

qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at [www.fda.gov/medwatch/report/mmp.htm](http://www.fda.gov/medwatch/report/mmp.htm).

If you have any questions, call Brian Strongin, R.Ph., M.B.A., Regulatory Project Manager at (301) 827-7473.

Sincerely,

*{See appended electronic signature page}*


Julie Beitz, M.D.  
Deputy Director  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

Enclosure



**Aloxi™ (Palonosetron Hydrochloride) Injection****Helsinn Healthcare S.A. NDA 21-372 Palonosetron: Proposed Labeling****DESCRIPTION**

Aloxi<sup>1</sup> (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a selective serotonin subtype 3 (5-HT<sub>3</sub>) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3a*S*)-2-[(*S*)-1-Azabicyclo [2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1*H*benz[*de*]isoquinoline hydrochloride. The empirical formula is C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O HCl, with a molecular weight of 332.87. Palonosetron hydrochloride exists as a single isomer and has the following structural formula:



Palonosetron hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, soluble in propylene glycol, and slightly soluble in ethanol and 2-propanol.

Aloxi injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. Each 5-ml vial of Aloxi injection contains 0.25 mg palonosetron base as hydrochloride, 207.5 mg mannitol, disodium edetate and citrate buffer in water for intravenous administration. The pH of the solution is 4.5 to 5.5.

**CLINICAL PHARMACOLOGY****Pharmacodynamics**

Palonosetron is a selective 5-HT<sub>3</sub> receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.

Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT<sub>3</sub> receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT<sub>3</sub> receptors located on vagal afferents to initiate the vomiting reflex.

<sup>1</sup> Pending trademark of Helsinn Healthcare SA  
Lugano, Switzerland  
COPYRIGHT © Helsinn Healthcare SA, 2003  
All rights reserved

The effect of palonosetron on blood pressure, heart rate, and ECG parameters including QTc were comparable to ondansetron and dolasetron in clinical trials. In non-clinical studies palonosetron possesses the ability to block ion channels involved in ventricular de- and re-polarization and to prolong action potential duration. In clinical trials, the dose-response relationship to the QTc interval has not been fully evaluated.

#### Pharmacokinetics

After intravenous dosing of palonosetron in healthy subjects and cancer patients, an initial decline in plasma concentrations is followed by a slow elimination from the body. Mean maximum plasma concentration ( $C_{max}$ ) and area under the concentration-time curve ( $AUC_{0-\infty}$ ) are generally dose-proportional over the dose range of 0.3–90  $\mu\text{g}/\text{kg}$  in healthy subjects and in cancer patients. Following single IV dose of palonosetron at 3  $\mu\text{g}/\text{kg}$  (or 0.21 mg/70 kg) to six cancer patients, mean ( $\pm$ SD) maximum plasma concentration was estimated to be  $5.6 \pm 5.5$  ng/mL and mean AUC was  $35.8 \pm 20.9$  ng·hr/mL.

#### **Distribution**

Palonosetron has a volume of distribution of approximately  $8.3 \pm 2.5$  L/kg. Approximately 62% of palonosetron is bound to plasma proteins.

#### **Metabolism**

Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 5-S-hydroxy-palonosetron. These metabolites each have less than 1% of the 5-HT<sub>3</sub> receptor antagonist activity of palonosetron. *In vitro* metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.

#### **Elimination**

After a single intravenous dose of 10  $\mu\text{g}/\text{kg}$  [<sup>14</sup>C]-palonosetron, approximately 80% of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40% of the administered dose. In healthy subjects the total body clearance of palonosetron was  $160 \pm 35$  mL/h/kg and renal clearance was  $66.5 \pm 18.2$  mL/h/kg. Mean terminal elimination half-life is approximately 40 hours.

#### Special Populations

##### **Geriatrics**

Population PK analysis and clinical safety and efficacy data did not reveal any differences between cancer patients  $\geq 65$  years of age and younger patients (18 to 64 years). No dose adjustment is required for these patients.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.